

Matthew G Law

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4090942/publications.pdf](https://exaly.com/author-pdf/4090942/publications.pdf)

Version: 2025-02-01

402
papers

29,600
citations

6267

75
h-index

4644

160
g-index

457
all docs

457
docs citations

457
times ranked

22770
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term HIV care outcomes under universal HIV treatment guidelines: A retrospective cohort study in 25 countries. <i>PLoS Medicine</i> , 2024, 21, e1004367.	8.1	4
2	HIV self-testing for men who have sex with men: an implementation trial in Indonesia. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 527-534.	1.5	5
3	Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012. <i>HIV Medicine</i> , 2022, 23, 134-145.	3.0	11
4	Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. <i>HIV Medicine</i> , 2022, 23, 274-286.	3.0	7
5	The impact of removing financial incentives and/or audit and feedback on chlamydia testing in general practice: A cluster randomised controlled trial (ACCEPT-able). <i>PLoS Medicine</i> , 2022, 19, e1003858.	8.1	6
6	Impact of Testing Strategies to Combat a Major Syphilis Outbreak Among Australian Aboriginal and Torres Strait Islander Peoples: A Mathematical Modeling Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.8	3
7	Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. <i>HIV Medicine</i> , 2022, 23, 895-910.	3.0	33
8	The response to COVID-19 among drug retail outlets in Indonesia: A cross-sectional survey of knowledge, attitudes, and practices. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 22, 100420.	3.6	3
9	The seasonality of infections in tropical Far North Queensland, Australia: A 21-year retrospective evaluation of the seasonal patterns of six endemic pathogens. <i>PLOS Global Public Health</i> , 2022, 2, e0000506.	2.2	11
10	Risk of variant Creutzfeldt-Jakob disease transmission by blood transfusion in Australia. <i>Vox Sanguinis</i> , 2022, 117, 1016-1026.	1.3	9
11	Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. <i>Lancet HIV</i> , 2022, 9, e414-e427.	8.2	31
12	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 632-637.	4.0	6
13	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. <i>Journal of Hepatology</i> , 2021, 74, 293-302.	2.9	29
14	The comparative ability of commonly used disease severity scores to predict death or a requirement for ICU care in patients hospitalised with possible sepsis in Yangon, Myanmar. <i>International Journal of Infectious Diseases</i> , 2021, 104, 543-550.	2.2	3
15	Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , 2021, 24, .	3.6	6
16	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 579-586.	1.9	20
17	Factors Associated With and Characteristic of HIV/Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 720-729.	1.9	1
18	Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial. <i>Lancet Infectious Diseases</i> , 2021, 21, 647-656.	15.7	26

#	ARTICLE	IF	CITATIONS
19	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2037-2044.	5.6	10
20	Azithromycin or Doxycycline for Asymptomatic Rectal <i>Chlamydia trachomatis</i> . <i>New England Journal of Medicine</i> , 2021, 384, 2418-2427.	25.5	46
21	Estimation of Potential HIV Transmission Risk in Recent Anal Intercourse Events among Men Who Have Sex with Men and Transgender Women in Bali, Indonesia. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 139.	2.3	4
22	Prevalence and determinants of inappropriate antibiotic dispensing at private drug retail outlets in urban and rural areas of Indonesia: a mixed methods study. <i>BMJ Global Health</i> , 2021, 6, e004993.	4.2	16
23	The longer-term effects of access to HIV self-tests on HIV testing frequency in high-risk gay and bisexual men: follow-up data from a randomised controlled trial. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 14, 100214.	3.6	5
24	Trends in Follow-Up Visits Among People Living With HIV: Results From the TREAT Asia and Australian HIV Observational Databases. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 70-78.	1.9	0
25	Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. <i>PLoS ONE</i> , 2021, 16, e0256926.	2.5	0
26	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment—Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	5.6	16
27	Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia. <i>PLoS Computational Biology</i> , 2021, 17, e1009385.	3.3	2
28	Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. <i>Lancet HIV</i> , 2021, 8, e766-e775.	8.2	53
29	Supplemental <i>Trichomonas vaginalis</i> testing is required to maintain control following a transition from Pap smear to HPV DNA testing for cervical screening: a mathematical modelling study. <i>Sexually Transmitted Infections</i> , 2020, 96, 76-78.	1.9	1
30	Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virus-positive Gay and Bisexual Men?. <i>Clinical Infectious Diseases</i> , 2020, 70, 106-113.	5.6	11
31	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 643-657.	2.9	123
32	Prevalence and Association of Perianal and Intra-Anal Warts with Composite High-Grade Squamous Intraepithelial Lesions Among Gay and Bisexual Men: Baseline Data from the Study of the Prevention of Anal Cancer. <i>AIDS Patient Care and STDs</i> , 2020, 34, 436-443.	2.8	9
33	Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients. <i>Journal of Clinical Neuroscience</i> , 2020, 81, 78-82.	1.7	2
34	Determining standardized causes of death of infants, children, and adolescents living with HIV in Asia. <i>Aids</i> , 2020, 34, 1527-1537.	2.6	15
35	Cardiovascular disease among people living with HIV in Brazil. <i>Tropical Medicine and International Health</i> , 2020, 25, 886-896.	2.1	8
36	PS-SiZer map to investigate significant features of body-weight profile changes in HIV infected patients in the leDEA Collaboration. <i>PLoS ONE</i> , 2020, 15, e0220165.	2.5	0

#	ARTICLE	IF	CITATIONS
37	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, .	3.6	5
38	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 240-250.	1.9	24
39	Comorbidity Medications Are Dispensed to More People Receiving Antiretroviral Therapy for HIV Compared with the General Population in Australia. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 291-296.	1.5	3
40	Treatment Modification after Second-Line Failure among People Living with HIV in Asia-Pacific. <i>Antiviral Therapy</i> , 2020, 25, 377-387.	2.1	2
41	An Expanded HIV Care Cascade: ART Uptake, Viral Load Suppression and Comorbidity Monitoring among Adults Living with HIV in Asia. <i>Antiviral Therapy</i> , 2020, 25, 275-285.	2.1	3
42	Clinical characteristics of overseas-born men who have sex with men (MSM) in the AHOD cohort and implications for clinical practice. <i>Sexually Transmitted Infections</i> , 2020, 96, 469-470.	1.9	1
43	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	9
44	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 650-657.	5.6	19
45	Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia. <i>Journal of Adolescent Health</i> , 2019, 65, 651-659.	2.3	0
46	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 1629-1634.	4.0	12
47	Strategies to improve control of sexually transmissible infections in remote Australian Aboriginal communities: a stepped-wedge, cluster-randomised trial. <i>The Lancet Global Health</i> , 2019, 7, e1553-e1563.	13.9	11
48	Incomplete recording of Indigenous identification status under-estimates the prevalence of Indigenous population attending Australian general practices: a cross sectional study. <i>BMC Health Services Research</i> , 2019, 19, .	2.7	6
49	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. <i>EClinicalMedicine</i> , 2019, 13, 91-100.	8.8	15
50	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	3.6	80
51	Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. <i>Journal of Hepatology</i> , 2019, 71, 281-288.	2.9	78
52	Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. <i>Scientific Reports</i> , 2019, 9, .	3.7	22
53	Cardiovascular Disease Incidence Projections in the TREAT Asia HIV Observational Database (TAHOD). <i>Antiviral Therapy</i> , 2019, 24, 271-279.	2.1	4
54	Estimating the number of people who inject drugs and syringe coverage in Australia, 2005-2016. <i>Drug and Alcohol Dependence</i> , 2019, 197, 108-114.	3.1	23

#	ARTICLE	IF	CITATIONS
55	Attrition and treatment outcomes among adolescents and youths living with HIV in the Thai National AIDS Program. <i>Journal of Virus Eradication</i> , 2019, 5, 33-40.	0.3	7
56	Incidence and time trends of anal cancer among people living with HIV in Australia. <i>Aids</i> , 2019, 33, 1361-1368.	2.6	24
57	Serious clinical events in HIV-positive persons with chronic kidney disease. <i>Aids</i> , 2019, 33, 2173-2188.	2.6	10
58	Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 562-571.	1.9	27
59	ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 456-462.	1.9	9
60	Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis". <i>Journal of Hepatology</i> , 2019, 71, 1254-1255.	2.9	0
61	Sexual practices have a significant impact on the vaginal microbiota of women who have sex with women. <i>Scientific Reports</i> , 2019, 9, .	3.7	28
62	HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme. <i>BMC Public Health</i> , 2019, 19, .	3.3	10
63	Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. <i>Journal of the International AIDS Society</i> , 2018, 21, .	3.6	9
64	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	5.6	98
65	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. <i>Lancet HIV</i> , 2018, 5, e172-e180.	8.2	29
66	Impact of replacing cytology with human papillomavirus testing for cervical cancer screening on the prevalence of <i>Trichomonas vaginalis</i> : a modelling study. <i>Sexually Transmitted Infections</i> , 2018, 94, 216-221.	1.9	6
67	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2018, 110, 598-607.	5.1	15
68	Reply to: "Who killed JR™: Chronic hepatitis C or alcohol use disorders?". <i>Journal of Hepatology</i> , 2018, 68, 1099-1100.	2.9	1
69	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. <i>Lancet HIV</i> , 2018, 5, e291-e300.	8.2	169
70	Rates of pelvic inflammatory disease and ectopic pregnancy in Australia, 2009-2014: ecological analysis of hospital data. <i>Sexually Transmitted Infections</i> , 2018, 94, 534-541.	1.9	14
71	Concordance of gonorrhoea of the rectum, pharynx and urethra in same-sex male partnerships attending a sexual health service in Melbourne, Australia. <i>BMC Infectious Diseases</i> , 2018, 18, .	2.7	15
72	Loss to follow-up and Associated Factors of Patients in the National AIDS Program in Thailand. <i>Antiviral Therapy</i> , 2018, 23, 529-538.	2.1	8

#	ARTICLE	IF	CITATIONS
73	Abacavir use and risk of recurrent myocardial infarction. <i>Aids</i> , 2018, 32, 79-88.	2.6	16
74	Reply to: "Direct antiviral agents and risk of HCC: Waiting for Godot", <i>Journal of Hepatology</i> , 2018, 68, 616-617.	2.9	2
75	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 473-481.	2.1	19
76	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. <i>Journal of Hepatology</i> , 2018, 68, 393-401.	2.9	65
77	People Born in Non-Main English Speaking Countries Are Less Likely to Start HIV Treatment Early in Australia: A National Cohort Analysis, 2014-15. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, e31-e34.	1.9	9
78	Aging of the HIV Population in Australia: A Modeling Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, e115-e116.	1.9	7
79	Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration. <i>Journal of the International AIDS Society</i> , 2018, 21, .	3.6	54
80	Characteristics, mortality and outcomes at transition for adolescents with perinatal HIV infection in Asia. <i>Aids</i> , 2018, 32, 1689-1697.	2.6	9
81	Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 754-767.	22.9	183
82	Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2018, 5, e553-e559.	8.2	18
83	Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial. <i>Lancet</i> , 2018, 392, 1413-1422.	35.3	57
84	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 579-588.	1.9	42
85	Associations between serum albumin and serious non-AIDS events among people living with HIV. <i>Aids</i> , 2018, 32, 1837-1848.	2.6	4
86	Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: global overview from the International Epidemiologic Databases to Evaluate AIDS (IeDEA). <i>Journal of the International AIDS Society</i> , 2018, 21, .	3.6	18
87	Early suboptimal ART adherence was associated with missed clinical visits in HIV-infected patients in Asia. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1560-1566.	1.5	9
88	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, .	2.7	23
89	The cascade of HIV care among key populations in Indonesia: a prospective cohort study. <i>Lancet HIV</i> , 2018, 5, e560-e568.	8.2	65
90	Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality Rates in Children Without Severe Immunodeficiency. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 8, 450-460.	1.5	4

#	ARTICLE	IF	CITATIONS
91	A pseudo-random patient sampling method evaluated. <i>Journal of Clinical Epidemiology</i> , 2017, 81, 129-139.	4.0	9
92	Effect of availability of HIV self-testing on HIV testing frequency in gay and bisexual men at high risk of infection (FORTH): a waiting-list randomised controlled trial. <i>Lancet HIV</i> , 2017, 4, e241-e250.	8.2	119
93	Growing challenges for HIV programmes in Asia: clinic population trends, 2003-2013. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1243-1254.	1.5	2
94	CD4:CD8 Ratio Comparison between Cohorts of HIV-Positive Asians and Caucasians upon Commencement of Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2017, 22, 659-668.	2.1	17
95	Life Expectancy after Initiation of Combination Antiretroviral Therapy in Thailand. <i>Antiviral Therapy</i> , 2017, 22, 393-402.	2.1	22
96	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. <i>Aids</i> , 2017, 31, 1261-1270.	2.6	16
97	Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer. <i>International Journal of STD and AIDS</i> , 2017, 28, 1282-1291.	1.3	9
98	Identifying factors that lead to the persistence of imported gonorrhoeae strains: a modelling study. <i>Sexually Transmitted Infections</i> , 2017, 93, 221-225.	1.9	6
99	HIV and Aging: Demographic Change in the Asia-Pacific Region. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e146-e148.	1.9	18
100	High HIV Prevalence and Risk Among Male Clients of Female Sex Workers in Hanoi and Ho Chi Minh City, Vietnam. <i>AIDS and Behavior</i> , 2017, 21, 2381-2393.	2.0	16
101	Attrition and Mortality of Children Receiving Antiretroviral Treatment through the Universal Coverage Health Program in Thailand. <i>Journal of Pediatrics</i> , 2017, 188, 210-216.e1.	2.1	11
102	First-Line Antiretroviral Treatment Outcomes and Durability in HIV-Infected Children Treated Through the Universal Coverage Health Program in Thailand. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 219-225.	1.9	2
103	Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. <i>Scientific Reports</i> , 2017, 7, .	3.7	25
104	All-cause mortality in HIV-positive adults starting combination antiretroviral therapy. <i>Aids</i> , 2017, 31, S31-S40.	2.6	25
105	Loss to Follow-up Trends in HIV-Positive Patients Receiving Antiretroviral Treatment in Asia From 2003 to 2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 555-562.	1.9	22
106	Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective. <i>Vaccine</i> , 2017, 35, 4923-4929.	3.2	39
107	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. <i>Journal of Hepatology</i> , 2017, 67, 1204-1212.	2.9	402
108	HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy—Results From the IeDEA Collaboration. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 319-329.	1.9	55

#	ARTICLE	IF	CITATIONS
109	The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the <sc>TREAT</sc> Asia <sc>HIV</sc> Observational Database (<sc>TAHOD</sc>). Journal of the International AIDS Society, 2017, 20, .	3.6	3
110	Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings. AIDS Research and Therapy, 2017, 14, .	2.3	0
111	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000â€2014). Hepatology Communications, 2017, 1, 736-747.	4.9	8
112	Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data. BMC Infectious Diseases, 2017, 17, .	2.7	4
113	The influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade diversity in young women. PLoS ONE, 2017, 12, e0171856.	2.5	89
114	Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 yearsâ€The Australian Positive & Peers Longevity Evaluation Study (APPLES). PLoS ONE, 2017, 12, e0184583.	2.5	33
115	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Medicine, 2017, 14, e1002424.	8.1	21
116	Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014. Journal of the International AIDS Society, 2017, 20, .	3.6	16
117	Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region. Open AIDS Journal, 2017, 11, 52-66.	0.6	12
118	Tenofovir-Based Antiretroviral Therapy in HBVâ€HIV Coinfection: Results from the TREAT Asia HIV Observational Database. Antiviral Therapy, 2016, 21, 27-35.	2.1	8
119	Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons. Current Opinion in HIV and AIDS, 2016, 11, 514-520.	3.6	48
120	HIV Viral Suppression in TREAT Asia HIV Observational Database Enrolled Adults on Antiretroviral Therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. Antiviral Therapy, 2016, 21, 725-730.	2.1	1
121	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. Aids, 2016, 30, 1731-1743.	2.6	50
122	Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. Journal of Hepatology, 2016, 65, 879-887.	2.9	30
123	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. Aids, 2016, 30, 1629-1637.	2.6	8
124	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. Aids, 2016, 30, 1583-1596.	2.6	10
125	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. Aids, 2016, 30, 2659-2663.	2.6	22
126	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, .	0.8	23

#	ARTICLE	IF	CITATIONS
127	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1212-1220.	4.0	39
128	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). <i>Journal of Hepatology</i> , 2016, 65, 1086-1093.	2.9	38
129	Improved Survival in HIV Treatment Programmes in Asia. <i>Antiviral Therapy</i> , 2016, 21, 517-527.	2.1	18
130	High hepatitis C virus (HCV) prevalence among men who have sex with men (MSM) in Vietnam and associated risk factors: 2010 Vietnam Integrated Behavioural and Biologic Cross-Sectional Survey. <i>Sexually Transmitted Infections</i> , 2016, 92, 542-549.	1.9	15
131	Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 589-597.	1.9	10
132	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. <i>Antiviral Therapy</i> , 2016, 21, 495-506.	2.1	21
133	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. <i>BMC Medicine</i> , 2016, 14, .	7.4	101
134	Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOE. <i>Tropical Medicine and International Health</i> , 2016, 21, 662-674.	2.1	12
135	The occurrence of Simpson's paradox if site-level effect was ignored in the TREAT Asia HIV Observational Database. <i>Journal of Clinical Epidemiology</i> , 2016, 76, 183-192.	4.0	3
136	Poor record linkage sensitivity biased outcomes in a linked cohort analysis. <i>Journal of Clinical Epidemiology</i> , 2016, 75, 70-77.	4.0	9
137	Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men. <i>AIDS and Behavior</i> , 2016, 20, 2372-2386.	2.0	9
138	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 214-223.	2.1	173
139	Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. <i>PLoS ONE</i> , 2016, 11, e0150512.	2.5	43
140	Recent Trends in Early Stage Response to Combination Antiretroviral Therapy in Australia. <i>Antiviral Therapy</i> , 2015, 20, 131-139.	2.1	5
141	Loss to follow-up in the Australian HIV Observational Database. <i>Antiviral Therapy</i> , 2015, 20, 731-741.	2.1	13
142	Implementation and Operational Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, e85-e92.	1.9	16
143	Implementation and Operational Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, e110-e119.	1.9	7
144	Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia. <i>Journal of the International AIDS Society</i> , 2015, 18, .	3.6	10

#	ARTICLE	IF	CITATIONS
145	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS ONE, 2015, 10, e0139981.	2.5	41
146	Subsidized optimal ART for HIV-positive temporary residents of Australia improves virological outcomes: results from the Australian HIV Observational Database Temporary Residents Access Study. Journal of the International AIDS Society, 2015, 18, 19392.	3.6	9
147	Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies. Current Opinion in HIV and AIDS, 2015, 10, 483-494.	3.6	18
148	Incident Bacterial Vaginosis (BV) in Women Who Have Sex With Women Is Associated With Behaviors That Suggest Sexual Transmission of BV. Clinical Infectious Diseases, 2015, 60, 1042-1053.	5.6	61
149	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine, 2015, 12, e1001809.	8.1	120
150	HIV-infection and comorbidities: a complex mix. Lancet HIV, the, 2015, 2, e265-e266.	8.2	3
151	Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S. AIDS Research and Therapy, 2015, 12, 3.	2.3	9
152	Efficacy of Second-Line Antiretroviral Therapy Among People Living With HIV/AIDS in Asia. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 186-195.	1.9	25
153	Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infectious Diseases, The, 2015, 15, 1314-1323.	15.7	53
154	Risk group characteristics and viral transmission clusters in South-East Asian patients infected with human immunodeficiency virus-1 (HIV-1) circulating recombinant form (CRF) 01_AE and subtype B. Kaohsiung Journal of Medical Sciences, 2015, 31, 445-453.	2.7	2
155	Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD). BMC Infectious Diseases, 2015, 15, .	2.7	6
156	Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study. Lancet Infectious Diseases, The, 2015, 15, 65-73.	15.7	38
157	Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment. Journal of Hepatology, 2015, 62, 269-277.	2.9	35
158	High HIV Prevalence and Associated Risk Factors Among Female Sexual Partners of Male Injection Drug Users (MWID) in Ho Chi Minh City, Vietnam. AIDS and Behavior, 2015, 20, 395-404.	2.0	7
159	Findings from Integrated Behavioral and Biologic Survey among Males Who Inject Drugs (MWID) - Vietnam, 2009-2010: Evidence of the Need for an Integrated Response to HIV, Hepatitis B Virus, and Hepatitis C Virus. PLoS ONE, 2015, 10, e0118304.	2.5	15
160	Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review. PLoS ONE, 2015, 10, e0141905.	2.5	43
161	Quilt Plots: A Simple Tool for the Visualisation of Large Epidemiological Data. PLoS ONE, 2014, 9, e85047.	2.5	6
162	The Significance of HIV -Blips™ in Resource-Limited Settings: Is It the Same? Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD). PLoS ONE, 2014, 9, e86122.	2.5	9

#	ARTICLE	IF	CITATIONS
163	Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial. <i>PLoS ONE</i> , 2014, 9, e99530.	2.5	5
164	Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. <i>PLoS ONE</i> , 2014, 9, e106525.	2.5	18
165	Factors Associated with Participation and Attrition in a Longitudinal Study of Bacterial Vaginosis in Australian Women Who Have Sex with Women. <i>PLoS ONE</i> , 2014, 9, e113452.	2.5	12
166	HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia. <i>Journal of the International AIDS Society</i> , 2014, 17, .	3.6	14
167	Chlamydia prevalence in young attenders of rural and regional primary care services in Australia: a cross-sectional survey. <i>Medical Journal of Australia</i> , 2014, 200, 170-175.	2.1	23
168	Factors associated with suboptimal adherence to antiretroviral therapy in Asia. <i>Journal of the International AIDS Society</i> , 2014, 17, .	3.6	31
169	Improving chlamydia knowledge should lead to increased chlamydia testing among Australian general practitioners: a cross-sectional study of chlamydia testing uptake in general practice. <i>BMC Infectious Diseases</i> , 2014, 14, .	2.7	7
170	Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 63-71.	3.6	12
171	Comparison of central and local HIV-1 RNA quantification from two international clinical trials. <i>Aids</i> , 2014, 28, 2480-2483.	2.6	0
172	Relationship Between Hyperglycemia and the Risk of Tuberculosis in Asian HIV-Positive Individuals in the Antiretroviral Therapy Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, e108-e111.	1.9	4
173	Impact of Antiretroviral Therapy on Opportunistic Infections of HIV-infected Children in the Therapeutic Research, Education and AIDS Training Asia Pediatric HIV Observational Database. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 747-752.	1.3	24
174	Eradicating syphilis, hepatitis C and HIV in MSM through frequent testing strategies. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 56-61.	3.5	23
175	Global burden of transmitted HIV drug resistance and HIV-exposure categories. <i>Aids</i> , 2014, 28, 2751-2762.	2.6	72
176	A Clinical Prediction Tool for Targeted Pre-antiretroviral Therapy Creatinine Testing Applied to the TREAT Asia HIV Observational Database Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, e131-e133.	1.9	0
177	Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 89-97.e13.	1.3	58
178	Improving Oral Human Papillomavirus Detection Using Toothbrush Sampling in HIV-Positive Men Who Have Sex with Men. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2206-2209.	4.1	11
179	The Influence of Behaviors and Relationships on the Vaginal Microbiota of Women and Their Female Partners: The WOW Health Study. <i>Journal of Infectious Diseases</i> , 2014, 209, 1562-1572.	4.0	64
180	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. <i>Lancet, The</i> , 2014, 384, 241-248.	35.3	758

#	ARTICLE	IF	CITATIONS
181	Improving the clinical prediction of detrusor overactivity by utilizing additional symptoms and signs to overactive bladder symptoms alone. <i>International Urogynecology Journal</i> , 2014, 25, 1115-1120.	1.4	9
182	The Impact of Wild-Type Reversion on Transmitted Resistance Surveillance. <i>Antiviral Therapy</i> , 2014, 19, 719-722.	2.1	4
183	Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. <i>Aids</i> , 2014, 28, 187-199.	2.6	55
184	Cancer Incidence in a Nationwide HIV/AIDS Patient Cohort in Taiwan in 1998â€“2009. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 463-472.	1.9	34
185	Determinants of Suicide and Accidental or Violent Death in the Australian HIV Observational Database. <i>PLoS ONE</i> , 2014, 9, e89089.	2.5	28
186	Testing Commercial Sex Workers for Sexually Transmitted Infections in Victoria, Australia: An Evaluation of the Impact of Reducing the Frequency of Testing. <i>PLoS ONE</i> , 2014, 9, e103081.	2.5	39
187	A New Method for Assessing How Sensitivity and Specificity of Linkage Studies Affects Estimation. <i>PLoS ONE</i> , 2014, 9, e103690.	2.5	31
188	Changes in Metabolic, Inflammatory and Coagulation Biomarkers after HIV Seroconversion â€“ the Health in Men (Him) Biomarker Substudy. <i>Antiviral Therapy</i> , 2013, 18, 355-359.	2.1	3
189	Population movement can sustain STI prevalence in remote Australian indigenous communities. <i>BMC Infectious Diseases</i> , 2013, 13, .	2.7	12
190	The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models. <i>BMC Infectious Diseases</i> , 2013, 13, .	2.7	1
191	Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. <i>Vaccine</i> , 2013, 31, 1931-1936.	3.2	8
192	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	5.6	56
193	The chlamydia knowledge, awareness and testing practices of Australian general practitioners and practice nurses: survey findings from the Australian Chlamydia Control Effectiveness Pilot (ACCEPT). <i>BMC Family Practice</i> , 2013, 14, .	3.2	10
194	Associations between immune depression and cardiovascular events in HIV infection. <i>Aids</i> , 2013, 27, 2735-2748.	2.6	52
195	Intensity of human prion disease surveillance predicts observed disease incidence. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1372-1377.	2.0	51
196	Near Elimination of Genital Warts in Australia Predicted With Extension of Human Papillomavirus Vaccination to Males. <i>Sexually Transmitted Diseases</i> , 2013, 40, 833-835.	1.3	39
197	Recurrence of Bacterial Vaginosis Is Significantly Associated With Posttreatment Sexual Activities and Hormonal Contraceptive Use. <i>Clinical Infectious Diseases</i> , 2013, 56, 777-786.	5.6	111
198	Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 456-463.	1.9	13

#	ARTICLE	IF	CITATIONS
199	Evaluating Immunologic Response and Clinical Deterioration in Treatment-Naive Patients Initiating First-Line Therapies Infected With HIV-1 CRF01_AE and Subtype B. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 293-300.	1.9	14
200	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, .	2.7	62
201	Rates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Region. <i>PLoS ONE</i> , 2013, 8, e64902.	2.5	13
202	Hormonal Contraception Is Associated with a Reduced Risk of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e73055.	2.5	121
203	Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. <i>Sexually Transmitted Infections</i> , 2012, 88, i33-i43.	1.9	46
204	Loss to Followup in HIV-Infected Patients from Asia-Pacific Region: Results from TAHOD. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-10.	1.0	31
205	Serum Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15): A Potential Screening Tool for the Prevention of Colon Cancer?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 337-346.	0.9	52
206	Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation: a placebo controlled crossover trial. <i>Heart</i> , 2012, 98, 282-290.	2.8	16
207	Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 70-75.	0.8	89
208	Estimating the cost-effectiveness of needle-syringe programs in Australia. <i>Aids</i> , 2012, 26, 2201-2210.	2.6	74
209	Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. <i>Aids</i> , 2012, 26, 1707-1717.	2.6	8
210	Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PRÉDICT): a multicentre, randomised, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 933-941.	15.7	70
211	Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy. <i>PLoS ONE</i> , 2012, 7, e48839.	2.5	64
212	Hepatitis C treatment outcomes in Australian clinics. <i>Medical Journal of Australia</i> , 2012, 196, 633-637.	2.1	23
213	Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. <i>Journal of the International AIDS Society</i> , 2012, 15, .	3.6	56
214	Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. <i>Journal of the International AIDS Society</i> , 2012, 15, 1-1.	3.6	85
215	Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. <i>Journal of the International AIDS Society</i> , 2012, 15, 5-5.	3.6	30
216	Increased mortality among Indigenous persons during and after release from prison in New South Wales. <i>Australian and New Zealand Journal of Public Health</i> , 2012, 36, 274-280.	1.7	15

#	ARTICLE	IF	CITATIONS
217	Human papillomavirus and head and neck cancers: emerging trends and improving survival. Australian and New Zealand Journal of Public Health, 2012, 36, 195-196.	1.7	2
218	Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatology Research, 2012, 42, 1175-1186.	3.2	6
219	High Rates of Late HIV Diagnosis Among People Who Inject Drugs Compared to Men Who Have Sex with Men and Heterosexual Men and Women in Australia. AIDS and Behavior, 2012, 17, 235-241.	2.0	6
220	Trends in mortality after diagnosis of hepatitis B or C infection: 1992â€“2006. Journal of Hepatology, 2011, 54, 879-886.	2.9	43
221	Trends in anal cancer in Australia, 1982â€“2005. Vaccine, 2011, 29, 2322-2327.	3.2	86
222	Counting the cost: estimating the number of deaths among recently released prisoners in Australia. Medical Journal of Australia, 2011, 195, 64-68.	2.1	43
223	Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Medical Journal of Australia, 2011, 194, 398-402.	2.1	40
224	Prospective evidence that HIV lipotrophy and visceral adiposity are partially independent processes. Open Access Journal of Clinical Trials, 2011, , 1.	0.8	0
225	Predictors and Outcomes of HIV-Infected Antiretroviral-Naive Patients With Discordant Responses to Combination Antiretroviral Treatment in Asian and Australian Populations: Results From APHOD. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e13-e15.	1.9	1
226	Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. Aids, 2011, 25, 1143-1151.	2.6	17
227	The Coding Causes of Death in HIV (CoDe) Project. Epidemiology, 2011, 22, 516-523.	3.1	133
228	Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocrine Journal, 2011, 58, 475-484.	1.7	19
229	Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1757-1764.	2.8	43
230	Increasing cancer mortality among opioidâ€­dependent persons in Australia: a new public health challenge for a disadvantaged population. Australian and New Zealand Journal of Public Health, 2011, 35, 220-225.	1.7	49
231	Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 2011, 14, 10-10.	3.6	23
232	Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health, 2011, 11, .	3.3	15
233	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. Journal of Infectious Diseases, 2011, 203, 780-790.	4.0	929
234	HIV-1 Drug Resistance Mutations Among Antiretroviral-Naive HIV-1-Infected Patients in Asia: Results From the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clinical Infectious Diseases, 2011, 52, 1053-1057.	5.6	40

#	ARTICLE	IF	CITATIONS
235	HIV and aging: an overview of an emerging issue. <i>Sexual Health</i> , 2011, 8, 449.	1.7	6
236	CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 72-79.	1.9	11
237	Disproportionate Impact of Combination Antiretroviral Therapy on AIDS Incidence in Australia: Results from a Modified Back-projection Model. <i>AIDS and Behavior</i> , 2011, 16, 360-367.	2.0	1
238	Clinical Predictors of Immune Reconstitution following Combination Antiretroviral Therapy in Patients from the Australian HIV Observational Database. <i>PLoS ONE</i> , 2011, 6, e20713.	2.5	30
239	Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. <i>Aids</i> , 2010, 24, 907-913.	2.6	213
240	Antiretroviral Therapy Outcomes of HIV-Infected Children in the TREAT Asia Pediatric HIV Observational Database. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 503-509.	1.9	39
241	Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. <i>Aids</i> , 2010, 24, 1877-1886.	2.6	68
242	Hospitalizations in a cohort of HIV patients in Australia, 1999â€“2007. <i>Aids</i> , 2010, 24, 1329-1339.	2.6	20
243	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086.	2.1	32
244	Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. <i>BMC Infectious Diseases</i> , 2010, 10, .	2.7	23
245	Reproducibility of adenosine stress cardiovascular magnetic resonance in multi-vessel symptomatic coronary artery disease. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2010, 12, 42.	4.7	24
246	Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. <i>Journal of the International AIDS Society</i> , 2010, 13, 51-51.	3.6	27
247	Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia. <i>PLoS ONE</i> , 2010, 5, e10981.	2.5	20
248	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2010, 201, 318-330.	4.0	548
249	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 491-501.	2.8	298
250	Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a "high-affinity" FcÎ³RIIa genotype. <i>Aids</i> , 2010, 24, 1983-1990.	2.6	35
251	Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia. <i>Journal of Hepatology</i> , 2010, 53, 43-49.	2.9	14
252	High Viral Fitness during Acute HIV-1 Infection. <i>PLoS ONE</i> , 2010, 5, e12631.	2.5	12

#	ARTICLE	IF	CITATIONS
253	Difference in Absolute CD4+ Count According to CD4 Percentage between Asian and Caucasian HIV-Infected Patients. <i>Journal of AIDS & Clinical Research</i> , 2010, 01, .	0.3	25
254	Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. <i>Brain</i> , 2009, 132, 493-501.	8.9	20
255	Long-Term Patterns in CD4 Response Are Determined by an Interaction Between Baseline CD4 Cell Count, Viral Load, and Time: The Asia Pacific HIV Observational Database (APHOD). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 513-520.	1.9	39
256	Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. <i>Aids</i> , 2009, 23, 2183-2190.	2.6	108
257	The Impact of Needle and Syringe Programs on HIV and HCV Transmissions in Injecting Drug Users in Australia: A Model-Based Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 462-469.	1.9	63
258	The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies. <i>Aids</i> , 2009, 23, 1245-1254.	2.6	19
259	Dietary Intake in HIV-Infected Men with Lipodystrophy: Relationships with Body Composition, Visceral Fat, Lipid, Glucose and Adipokine Metabolism. <i>Current HIV Research</i> , 2009, 7, 456-461.	0.8	8
260	Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. <i>Diabetes Care</i> , 2009, 32, 474-480.	9.5	29
261	Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009, 49, 811-812.	5.6	1
262	Evolution of CD4⁺ T Cell Count in HIV-1-Infected Adults Receiving Antiretroviral Therapy with Sustained Long-Term Virological Suppression. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 569-576.	1.5	9
263	Short-term Clinical Disease Progression in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results from the TREAT Asia HIV Observational Database. <i>Clinical Infectious Diseases</i> , 2009, 48, 940-950.	5.6	24
264	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. <i>Circulation</i> , 2009, 119, 805-811.	19.4	85
265	TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. <i>Journal of Virological Methods</i> , 2009, 159, 185-193.	1.7	33
266	Recurrent urinary tract infections in women with symptoms of pelvic floor dysfunction. <i>International Urogynecology Journal</i> , 2009, 20, 837-842.	1.4	29
267	Characterizing trends in HIV infection among men who have sex with men in Australia by birth cohorts: results from a modified back-projection method. <i>Journal of the International AIDS Society</i> , 2009, 12, 19-19.	3.6	23
268	Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. <i>Addiction</i> , 2009, 104, 1363-1372.	6.1	80
269	Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. <i>Addiction</i> , 2009, 104, 2049-2056.	6.1	27
270	Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. <i>Nature Medicine</i> , 2009, 15, 285-292.	25.6	237

#	ARTICLE	IF	CITATIONS
271	Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 436-442.	2.8	12
272	The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997-2006. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1648-1654.	2.8	53
273	Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. <i>Drug and Alcohol Dependence</i> , 2009, 105, 9-15.	3.1	297
274	AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. <i>Aids</i> , 2009, 23, 2323-2336.	2.6	28
275	Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region. <i>Journal of Antivirals & Antiretrovirals</i> , 2009, 01, 028-035.	3.3	2
276	An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. <i>Liver International</i> , 2008, 28, 525-531.	4.2	61
277	Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 922-929.	2.8	24
278	Relation between HIV viral load and infectiousness: a model-based analysis. <i>Lancet, The</i> , 2008, 372, 314-320.	35.3	294
279	HIV transmission under highly active antiretroviral therapy - Authors' reply. <i>Lancet, The</i> , 2008, 372, 1807.	35.3	0
280	Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. <i>Diabetes Care</i> , 2008, 31, 1224-1229.	9.5	412
281	Immediate Postvoid Residual Volumes in Women With Symptoms of Pelvic Floor Dysfunction. <i>Obstetrics and Gynecology</i> , 2008, 111, 1305-1312.	1.4	49
282	Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood. <i>PLoS Pathogens</i> , 2008, 4, e1000055.	4.5	44
283	Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients. <i>Circulation</i> , 2008, 118, .	19.4	30
284	Does the presenting bladder volume at urodynamics have any diagnostic relevance?. <i>International Urogynecology Journal</i> , 2008, 20, 319-324.	1.4	5
285	Country review: Australia. , 2008, , 85-102.		0
286	Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoalbuminemia. <i>Diabetes Care</i> , 2007, 30, 113-119.	9.5	259
287	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2007, 356, 1723-1735.	25.5	1,291
288	Increased Incidence of Squamous Cell Carcinoma of Eye After Kidney Transplantation. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1340-1342.	5.1	31

#	ARTICLE	IF	CITATIONS
289	The Safety, Efficacy, and Pharmacokinetic Profile of a Switch in Antiretroviral Therapy to Saquinavir, Ritonavir, and Atazanavir Alone for 48 Weeks and a Switch in the Saquinavir Formulation. <i>Clinical Infectious Diseases</i> , 2007, 44, 1475-1483.	5.6	13
290	Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. <i>Aids</i> , 2007, 21, 2445-2453.	2.6	154
291	Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. <i>Aids</i> , 2007, 21, 2315-2321.	2.6	162
292	Modelling the hepatitis C virus epidemic in Australia. <i>Drug and Alcohol Dependence</i> , 2007, 91, 228-235.	3.1	112
293	Causes of death in hepatitis B and C: a methodological issue. <i>Lancet, The</i> , 2007, 370, 1033.	35.3	3
294	Suicide risk among recently released prisoners in New South Wales, Australia. <i>Medical Journal of Australia</i> , 2007, 187, 387-390.	2.1	96
295	Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). <i>AIDS Research and Therapy</i> , 2007, 4, 18.	2.3	23
296	A feasible method for linkage studies avoiding clerical review: linkage of the national HIV/AIDS surveillance databases with the National Death Index in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2007, 31, 308-312.	1.7	8
297	Liver cancer and hepatitis B and C in New South Wales, 1990â€“2002: a linkage study. <i>Australian and New Zealand Journal of Public Health</i> , 2007, 31, 475-482.	1.7	30
298	Factors associated with mortality in a cohort of Australian prisoners. <i>European Journal of Epidemiology</i> , 2007, 22, 417-428.	5.4	101
299	Effect of Transient Antiretroviral Treatment during acute HIV Infection: Comparison of the Quest Trial Results with CASCADE Natural History Study. <i>Antiviral Therapy</i> , 2007, 12, 189-194.	2.1	21
300	Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. <i>Lancet, The</i> , 2006, 368, 938-945.	35.3	229
301	Mortality in patients with hepatitis B or hepatitis C â€“ Authors' reply. <i>Lancet, The</i> , 2006, 368, 1767.	35.3	3
302	Cancer Incidence Before and After Kidney Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2823.	13.7	930
303	Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study. <i>Journal of Hepatology</i> , 2006, 45, 197-203.	2.9	124
304	Cancer Incidence among Australian Nuclear Industry Workers. <i>Journal of Occupational Health</i> , 2006, 48, 358-365.	1.9	16
305	Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention ??? the HIV polypill study. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 482-487.	3.6	4
306	Response from the authors. <i>Australian and New Zealand Journal of Public Health</i> , 2006, 30, 189.	1.7	0

#	ARTICLE	IF	CITATIONS
307	Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity?. International Urogynecology Journal, 2006, 18, 123-128.	1.4	48
308	Methods estimating the prevalence of problem drug use. International Journal of Drug Policy, 2006, 17, 154-158.	3.5	9
309	The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 192-202.	1.9	24
310	Changes in Body Composition and Mitochondrial Nucleic Acid Content in Patients Switched from Failed Nucleoside Analogue Therapy to Ritonavir-Boosted Indinavir and Efavirenz. Journal of Infectious Diseases, 2006, 194, 642-650.	4.0	29
311	A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study. PLOS Clinical Trials, 2006, 1, e18.	3.4	22
312	Has the true prevalence of voiding difficulty in urogynecology patients been underestimated?. International Urogynecology Journal, 2006, 18, 53-56.	1.4	45
313	Evaluation of the HIV Lipodystrophy Case Definition in a Placebo-Controlled, 144-Week Study in Antiretroviral-Naive Adults. Antiviral Therapy, 2006, 11, 179-186.	2.1	19
314	Buffalo Hump Seen in HIV-Associated Lipodystrophy is Associated With Hyperinsulinemia But Not Dyslipidemia. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 156-162.	1.9	48
315	The TREAT Asia HIV Observational Database. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 174-179.	1.9	139
316	HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. Aids, 2005, 19, 169-178.	2.6	27
317	Mortality among prisoners: how accurate is the Australian National Death Index?. Australian and New Zealand Journal of Public Health, 2005, 29, 572-575.	1.7	33
318	Mortality rates among nuclear industry workers at Lucas Heights Science and Technology Centre. Australian and New Zealand Journal of Public Health, 2005, 29, 229-237.	1.7	18
319	Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine, 2005, 23, 5009-5021.	3.2	53
320	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	2.1	101
321	The CpG Island Methylator Phenotype Is Not Associated with a Personal or Family History of Cancer. Cancer Research, 2004, 64, 7618-7621.	0.6	23
322	Progression of Lipodystrophy (LD) with Continued Thymidine Analogue Usage: Long-Term Follow-Up from a Randomized Clinical Trial (The PIILR Study). HIV Clinical Trials, 2004, 5, 192-200.	2.2	13
323	Modeling Trends in HIV Incidence Among Homosexual Men in Australia 1995-2006. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 401-406.	1.9	24
324	Estimates of chronic hepatitis B virus infection in Australia, 2000. Australian and New Zealand Journal of Public Health, 2004, 28, 212-216.	1.7	92

#	ARTICLE	IF	CITATIONS
325	Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN γ or IL-12. <i>Vaccine</i> , 2004, 23, 188-197.	3.2	43
326	No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2004, 363, 429-438.	35.3	225
327	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet</i> , The, 2004, 364, 51-62.	35.3	255
328	Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: A meta-analysis of six prospective, randomized, comparative studies. <i>Clinical Therapeutics</i> , 2004, 26, 92-97.	2.9	71
329	Effectiveness of needle and syringe programmes for preventing HIV transmission. <i>International Journal of Drug Policy</i> , 2003, 14, 353-357.	3.5	80
330	Selective exclusion of treatment arms in multi-arm randomized clinical trials. <i>Statistics in Medicine</i> , 2003, 22, 19-30.	1.7	5
331	The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2003, 38, 349-356.	2.9	62
332	Epidemiology of hepatitis C virus infection in Australia. <i>Journal of Clinical Virology</i> , 2003, 26, 171-184.	3.1	154
333	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. <i>International Journal of Epidemiology</i> , 2003, 32, 717-724.	5.2	125
334	The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. <i>International Journal of Epidemiology</i> , 2003, 32, 708-714.	5.2	49
335	Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-1193.	2.6	750
336	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	25.5	1,460
337	Centralized Assessment of Dual-Energy X-ray Absorptiometry (DEXA) in Multicenter Studies of HIV-Associated Lipodystrophy. <i>HIV Clinical Trials</i> , 2003, 4, 45-49.	2.2	13
338	Limited Evolution of HIV Antiretroviral Drug Resistance-Associated Mutations During the Performance of Drug Resistance Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 57-61.	1.9	11
339	An Objective Lipodystrophy Severity Grading Scale Derived From the Lipodystrophy Case Definition Score. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 571-576.	1.9	76
340	Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase. <i>Medical Journal of Australia</i> , 2003, 178, 197-198.	2.1	7
341	Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. <i>Aids</i> , 2003, 17, 1094-1096.	2.6	44
342	Natural History Models for Hepatitis C-Related Liver Disease: Different Disease Progression Parameters for Different Settings. <i>Antiviral Therapy</i> , 2003, 8, 365-372.	2.1	19

#	ARTICLE	IF	CITATIONS
343	HIV Lipodystrophy Case Definition using Artificial Neural Network Modelling. <i>Antiviral Therapy</i> , 2003, 8, 435-441.	2.1	11
344	Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection. <i>Journal of Immunology</i> , 2002, 169, 4657-4666.	0.6	46
345	Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy<SUBTITLE>A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 207.	13.7	250
346	A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. <i>Aids</i> , 2002, 16, 2195-2200.	2.6	74
347	Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study. <i>HIV Clinical Trials</i> , 2002, 3, 177-185.	2.2	45
348	Estimation of Risk of Cancers before Occurrence of Acquired Immunodeficiency Syndrome in Persons Infected with Human Immunodeficiency Virus. <i>American Journal of Epidemiology</i> , 2002, 155, 153-158.	3.6	21
349	Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. <i>Aids</i> , 2002, 16, 1155-1161.	2.6	193
350	Is severe liver disease a common outcome for people with chronic hepatitisC?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 423-430.	2.8	76
351	Modelling HIV incidence in gay men: increased treatment, unsafe sex and sexually transmissible infections. <i>Aids</i> , 2002, 16, 499-501.	2.6	11
352	Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control. <i>Aids</i> , 2002, 16, 2489-2491.	2.6	18
353	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. <i>Antiviral Therapy</i> , 2002, 7, 271-281.	2.1	14
354	The cost of hepatitis C and the costâ€ effectiveness of its prevention. <i>Health Policy</i> , 2001, 58, 121-131.	3.0	16
355	Modelling the effect of combination antiretroviral treatments on HIV incidence. <i>Aids</i> , 2001, 15, 1287-1294.	2.6	104
356	A Randomized Trial of Nelfinavir, Ritonavir, or Delavirdine in Combination with Saquinavir-SGC and Stavudine in Treatment-Experienced HIV-1-Infected Patients. <i>HIV Clinical Trials</i> , 2001, 2, 97-107.	2.2	8
357	Back-projection estimates of the number of dependent heroin users in Australia. <i>Addiction</i> , 2001, 96, 433-443.	6.1	43
358	Estimating progression to cirrhosis in chronic hepatitis C virus infection. <i>Hepatology</i> , 2001, 34, 809-816.	11.6	502
359	Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. <i>Aids</i> , 2001, 15, 629-633.	2.6	134
360	Baseline Antiretroviral Drug Susceptibility Influences Treatment Response in Patients Receiving Saquinavir-Enhancing Therapy. <i>HIV Clinical Trials</i> , 2001, 2, 445-452.	2.2	7

#	ARTICLE	IF	CITATIONS
361	HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. <i>Aids</i> , 2001, 15, 1811-1822.	2.6	147
362	A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. <i>Aids</i> , 2000, 14, F25-F32.	2.6	501
363	A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. <i>Aids</i> , 2000, 14, 1171-1180.	2.6	70
364	Problems with Publishing Results of Interim Analyses of Randomized Clinical Trials. <i>HIV Clinical Trials</i> , 2000, 1, 30-36.	2.2	4
365	B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. <i>Aids</i> , 2000, 14, 133-140.	2.6	118
366	Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. <i>Aids</i> , 2000, 14, 197-201.	2.6	55
367	Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. <i>Medical Journal of Australia</i> , 2000, 173, 403-405.	2.1	69
368	How many dependent heroin users are there in Australia?. <i>Medical Journal of Australia</i> , 2000, 173, 528-531.	2.1	121
369	A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin-2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus-Infected Patients with CD4+Cell Counts $\geq 350/\text{mm}^3$. <i>Journal of Infectious Diseases</i> , 2000, 181, 1614-1621.	4.0	66
370	Lipodystrophy following antiretroviral therapy of primary HIV infection. <i>Aids</i> , 2000, 14, 2406-2407.	2.6	40
371	Therapeutic Vaccination with p24-VLP and Zidovudine Augments HIV-Specific Cytotoxic T Lymphocyte Activity in Asymptomatic HIV-Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 105-113.	1.5	27
372	Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin. <i>Cancer Investigation</i> , 1999, 17, 479-485.	1.7	3
373	AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment. <i>Aids</i> , 1999, 13, 263-269.	2.6	22
374	Risk of cancer in people with AIDS. <i>Aids</i> , 1999, 13, 839-843.	2.6	161
375	Impact of Early HIV-1 RNA and T-Lymphocyte Dynamics During Primary HIV-1 Infection on the Subsequent Course of HIV-1 RNA Levels and CD4+ T-Lymphocyte Counts in the First Year of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 22, 437.	1.9	24
376	Impact of Early HIV-1 RNA and T-Lymphocyte Dynamics During Primary HIV-1 Infection on the Subsequent Course of HIV-1 RNA Levels and CD4+ T-Lymphocyte Counts in the First Year of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 22, 437.	1.9	19
377	Rising incidence of oesophageal adenocarcinoma in men in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 356-362.	2.8	93
378	A comparison of adjuvant psychological therapy and supportive counselling in patients with cancer. , 1998, 7, 218-228.		91

#	ARTICLE	IF	CITATIONS
379	Patterns of Viral Dynamics during Primary Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 1998, 178, 1812-1815.	4.0	79
380	Predictors of Progression in Long-Term Nonprogressors. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 117-121.	1.5	26
381	Time trends in HIV infection among pregnant women in Europe. <i>Aids</i> , 1998, 12, 211-215.	2.6	9
382	A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. <i>Aids</i> , 1998, 12, F51-F58.	2.6	2,012
383	HIV disease progression in Australia in the time of combination antiretroviral therapies. <i>Medical Journal of Australia</i> , 1998, 169, 469-472.	2.1	40
384	Levels of Human Immunodeficiency Virus Type 1 RNA in Cerebrospinal Fluid Correlate with AIDS Dementia Stage. <i>Journal of Infectious Diseases</i> , 1997, 175, 963-966.	4.0	245
385	Prospective Analysis of Seizures Occurring in Human Immunodeficiency Virus Type-1 Infection. <i>Journal of Neuro-AIDS</i> , 1997, 1, 59-69.	0.0	31
386	Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. <i>Radiotherapy and Oncology</i> , 1997, 42, 121-135.	0.9	83
387	Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. <i>Radiotherapy and Oncology</i> , 1997, 44, 229-236.	0.9	62
388	Incidence of HIV infection in a cohort of homosexually active men. <i>Australian and New Zealand Journal of Public Health</i> , 1997, 21, 587-589.	1.7	5
389	Author's Reply: Survival analysis of randomized clinical trials adjusted for patients who switch treatments by M. G. Law and J. M. Kaldor, <i>Statistics in Medicine</i> , 15, 2069-2076 (1996). <i>Statistics in Medicine</i> , 1997, 16, 2620-2621.	1.7	1
390	Accuracy of pelvic radiotherapy: prospective analysis of 90 patients in a randomised trial of blocked versus standard radiotherapy. <i>Radiotherapy and Oncology</i> , 1996, 39, 19-29.	0.9	42
391	Age-specific HIV incidence among homosexually active men in Australia. <i>Medical Journal of Australia</i> , 1996, 164, 715-718.	2.1	8
392	Sample size calculations for within-patient comparisons with a binary or survival endpoint. <i>Contemporary Clinical Trials</i> , 1996, 17, 221-225.	2.8	0
393	SURVIVAL ANALYSES OF RANDOMIZED CLINICAL TRIALS ADJUSTED FOR PATIENTS WHO SWITCH TREATMENTS. , 1996, 15, 2069-2076.		19
394	Estimation of cumulative HIV incidence in Australia, based on national case reporting. <i>Australian and New Zealand Journal of Public Health</i> , 1996, 20, 215-217.	1.7	5
395	Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Does Not Adversely Affect Outcome at 1 Year. <i>Journal of Infectious Diseases</i> , 1996, 174, 195-198.	4.0	34
396	CD8+ Lymphocyte Responses to Antiretroviral Therapy of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, 320-326.	0.3	48

#	ARTICLE	IF	CITATIONS
397	The role of initial AIDS-defining illness in survival following AIDS. <i>Aids</i> , 1995, 9, 57-64.	2.6	47
398	Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast. <i>International Journal of Cancer</i> , 1995, 64, 274-279.	4.5	38
399	The Mini-MAC. <i>Journal of Psychosocial Oncology</i> , 1994, 12, 33-46.	2.1	299
400	Adjuvant psychological therapy for patients with cancer: Outcome at one year. <i>Psycho-Oncology</i> , 1994, 3, 39-46.	3.2	98
401	Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. <i>Radiotherapy and Oncology</i> , 1994, 30, 109-120.	0.9	82
402	Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993, 44, 583-587.	2.4	30